Li-Zhi Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Li-Zhi Cheng has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Chen Zhou
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai China
1 shared publicationDan‐Ling Huang
Institute for Inheritance‐Based Innovation of Chinese Medicine, School of Pharmaceutical Sciences Shenzhen University Health Science Center Shenzhen China
1 shared publicationJiang Zeng-Rong
Department of System Engineering and Mathematics, National University of Defense Technology, Changsha, Hunan, China
1 shared publicationJia‐Hao Zhang
State Key Laboratory of Natural Medicines, Department of Pharmacology, School of Pharmacy China Pharmaceutical University Nanjing China
1 shared publicationMan Dou
State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, PR China; Faculty of Life Science and Engineering, Kunming University of Science and Technology, Kunming, 650500, PR China
1 shared publicationNai‐Xia Zhang
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai China
1 shared publication
Latest Publications
- 18 August 2023
- Published by Wiley in British Journal of Pharmacology
- Vol. 180 (23) , 3071-3091
Pharmacological targeting of Axin2 suppresses cell growth and metastasis in colorectal cancer
Background and Purpose: The scaffold molecule Axin2 is constitutively activated in colorectal cancer (CRC) and functions as a potent promoter of CRC behaviour. Pharmacological targeting of Axin2 may therefore exert a therapeutic effect in patients with CRC. Here, we discovered a potent small‐molecule inhibitor of Axin2, based on the mechanism by which Axin2 is regulated post‐translationally, and investigated its antitumour effects.Experimental Approach: Compound discovery and its inhibitory action on Axin2 protein were revealed by microscale thermophoresis, in vitro kinase assay, quantitative kinetic assay, immunoblotting/immunoprecipitation, RT‐qPCR and cycloheximide pulse‐chase assay. Compound antitumour effects and the underlying mechanisms were evaluated in multiple cell‐based assays and mouse models.Key Results: We discovered that glycogen synthase kinase 3β (GSK3β) phosphorylates Axin2 at two consensus motifs and coupled Axin2 phosphorylation to its ubiquitination (mediated by the E3 ligase β‐Trcp2) and proteasomal degradation. The binding of Axin2 to GSK3β in CRC cells is faint, which enables most of the Axin2 protein to maintain an unphosphorylated status and thereby permits the cells to preserve high levels of Axin2. Importantly, we identified a small‐molecule compound CW85319 that enhances Axin2's interaction with GSK3β via forming a high affinity for Axin2. Treatment of CRC cells with CW85319 enhanced Axin2 binding with GSK3β, thereby promoting Axin2 phosphorylation, subsequent ubiquitination, and degradation. Furthermore, we demonstrated that CW85319 efficiently suppressed Axin2‐driven CRC growth and metastasis, without eliciting side toxicity.Conclusions and Implications: These findings suggest that pharmacological targeting of Axin2 by CW85319 may provide therapeutic benefits against certain human cancers, especially CRC.
- 18 August 2023
- Published by Wiley in British Journal of Pharmacology
- Vol. 180 (23) , 3071-3091
Pharmacological targeting of Axin2 suppresses cell growth and metastasis in colorectal cancer
Background and Purpose: The scaffold molecule Axin2 is constitutively activated in colorectal cancer (CRC) and functions as a potent promoter of CRC behaviour. Pharmacological targeting of Axin2 may therefore exert a therapeutic effect in patients with CRC. Here, we discovered a potent small‐molecule inhibitor of Axin2, based on the mechanism by which Axin2 is regulated post‐translationally, and investigated its antitumour effects.Experimental Approach: Compound discovery and its inhibitory action on Axin2 protein were revealed by microscale thermophoresis, in vitro kinase assay, quantitative kinetic assay, immunoblotting/immunoprecipitation, RT‐qPCR and cycloheximide pulse‐chase assay. Compound antitumour effects and the underlying mechanisms were evaluated in multiple cell‐based assays and mouse models.Key Results: We discovered that glycogen synthase kinase 3β (GSK3β) phosphorylates Axin2 at two consensus motifs and coupled Axin2 phosphorylation to its ubiquitination (mediated by the E3 ligase β‐Trcp2) and proteasomal degradation. The binding of Axin2 to GSK3β in CRC cells is faint, which enables most of the Axin2 protein to maintain an unphosphorylated status and thereby permits the cells to preserve high levels of Axin2. Importantly, we identified a small‐molecule compound CW85319 that enhances Axin2's interaction with GSK3β via forming a high affinity for Axin2. Treatment of CRC cells with CW85319 enhanced Axin2 binding with GSK3β, thereby promoting Axin2 phosphorylation, subsequent ubiquitination, and degradation. Furthermore, we demonstrated that CW85319 efficiently suppressed Axin2‐driven CRC growth and metastasis, without eliciting side toxicity.Conclusions and Implications: These findings suggest that pharmacological targeting of Axin2 by CW85319 may provide therapeutic benefits against certain human cancers, especially CRC.
- 1 January 2017
- Published by Elsevier in Fitoterapia
- Vol. 116, 93-98
Racemic alkaloids from the fungus Ganoderma cochlear
- 1 January 2017
- Published by Elsevier in Fitoterapia
- Vol. 116, 93-98
Racemic alkaloids from the fungus Ganoderma cochlear
- 24 December 2002
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 1, 166-169
Real transform algorithm for computing discrete circular deconvolution
Fast computation of the discrete deconvolution is very important in image/video signal processing. We develop a real transform algorithm for calculating the discrete circular deconvolution by substituting the fast Fourier transform (FFT) defined in the complex domain. It is shown that the computational cost of the algorithm is about half of the traditional FFT. Furthermore, the algorithm has a weak numerical stability.
- 24 December 2002
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 1, 166-169
Real transform algorithm for computing discrete circular deconvolution
Fast computation of the discrete deconvolution is very important in image/video signal processing. We develop a real transform algorithm for calculating the discrete circular deconvolution by substituting the fast Fourier transform (FFT) defined in the complex domain. It is shown that the computational cost of the algorithm is about half of the traditional FFT. Furthermore, the algorithm has a weak numerical stability.